These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 3493070)

  • 1. Immune reactivity in SL2 lymphoma-bearing mice compared with SL2-immunized mice.
    De Weger RA; Wilbrink B; Moberts RM; Mans D; Oskam R; Den Otter W
    Cancer Immunol Immunother; 1987; 24(1):25-36. PubMed ID: 3493070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific tumoricidal activity of cytotoxic macrophages and cytotoxic lymphocytes.
    Dullens HF; Schakenraad S; Oostdijk A; Vuist W; Van der Maas M; Den Otter W
    Cancer Immunol Immunother; 1986; 22(2):100-6. PubMed ID: 3487380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
    Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
    Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of host lymphocytes and host macrophages in antitumor reactions after injection of sensitized lymphocytes and tumor target cells into naive mice.
    Dullens HF; Vuist W; Van der Maas M; Den Otter W
    Cancer Immunol Immunother; 1986; 23(2):113-8. PubMed ID: 3536093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of immunomodulators on specific tumor immunity induced by liposome-encapsulated tumor-associated antigens.
    Bergers JJ; Den Otter W; Dullens HF; De Groot JW; Steerenberg PA; Filius PM; Crommelin DJ
    Int J Cancer; 1994 Mar; 56(5):721-6. PubMed ID: 8314349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: characterization of the effector population and evidence for the role of the host's non-T cells.
    Colombo MP; Parenza M; Parmiani G
    Cancer Immunol Immunother; 1985; 20(3):198-204. PubMed ID: 3851699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte induced macrophage cytotoxicity: characterization of the macrophage cytotoxicity-inducing lymphocyte.
    Pels E; de Weger RA; den Otter W
    Immunobiology; 1984 Jan; 166(1):84-95. PubMed ID: 6201434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of tumor cells after injection into immunized hosts compared with the eradication of tumor cells after transfer of immune peritoneal exudates into tumor-bearing recipients.
    Den Otter W; De Groot JW; Dullens HF
    Cancer Immunol Immunother; 1983; 16(2):72-6. PubMed ID: 6559103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the induction of macrophage cytotoxicity by the specific T lymphocyte factor, specific macrophage arming factor (SMAF), and the lymphokine, macrophage activating factor (MAF).
    De Groot JW; De Weger RA; Vandebriel RJ; Den Otter W
    Immunobiology; 1989 Jun; 179(2-3):131-44. PubMed ID: 2676851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocyte-induced macrophage cytotoxicity. Production of specific macrophage arming factor by sensitized Lyt 1+2+ T-lymphocytes.
    Pels E; De Weger RA; Den Otter W
    Int Arch Allergy Appl Immunol; 1984; 74(2):140-6. PubMed ID: 6609130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of the omental lymphoid organ in the induction of peritoneal immunity against tumor cells.
    Dullens HF; Rademakers LH; Doffemont M; Van Veen PT; Bulder R; Den Otter W
    Invasion Metastasis; 1993; 13(5):267-76. PubMed ID: 7960579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of correlation between in vivo peroxidatic activity patterns and tumoricidal activity in vitro of peritoneal macrophages after intraperitoneal immunization with tumor cells.
    Dullens HF; van Walraven R; Klomberg M; Rademakers LP; de Goey IC; den Otter W
    Immunobiology; 1988 Jul; 177(3):293-304. PubMed ID: 3169842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences between graft-versus-leukemia and graft-versus-host reactivity. I. Interaction of donor immune T cells with tumor and/or host cells.
    Rocha M; Umansky V; Lee KH; Hacker HJ; Benner A; Schirrmacher V
    Blood; 1997 Mar; 89(6):2189-202. PubMed ID: 9058744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effector phenotypes and mechanisms of antitumor immune reactivity of tumor-immunized and tumor-bearing mice in two syngeneic tumors.
    Fuyama S; Komatsu H; Arai S
    Cell Immunol; 1991 Oct; 137(1):200-15. PubMed ID: 1679379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfer of tumor immunity by both CD4+ and CD8+ tumor infiltrating T lymphocytes activated in vivo by IL-2 therapy of tumor bearing mice.
    Maas RA; Becker MJ; Weimar IS; De Nooy JC; Dullens HF; Den Otter WD
    Immunobiology; 1993 Jul; 188(3):281-92. PubMed ID: 7901148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.
    Germain RN; Williams RM; Benacerraf B
    Am J Pathol; 1976 Dec; 85(3):661-74. PubMed ID: 826167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of specific macrophage-arming factor precedes cytotoxic T lymphocyte activity in vivo during tumor rejection.
    Dullens HF; De Weger RA; Van der Maas M; Den Besten PJ; Vandebriel RJ; Den Otter W
    Cancer Immunol Immunother; 1989; 30(1):28-33. PubMed ID: 2598173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arming of macrophages with lymphocytes from mice immunized with tumor tissue.
    Horowitz M; Argyris BF
    Immunol Commun; 1977; 6(3):297-319. PubMed ID: 69610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy with antibody-coated immune and hyperimmune peritoneal cells in a murine lymphoma system.
    Dullens HF; De Weger RA; Woutersen RA; Den Otter W
    J Natl Cancer Inst; 1975 Jan; 54(1):77-82. PubMed ID: 1167595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Passive adoptive immunotherapy of low-immunogenic BALB/c lymphoma by syngeneic alloimmune T lymphocytes.
    Colombo MP; Arioli I; Parmiani G
    Int J Cancer; 1984 Dec; 34(6):807-13. PubMed ID: 6334656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.